BAD response to NICE Proposed Single Technology Appraisal: Belimumab for the treatment of active systemic lupus erythematosus (Sep 2010)

BAD response to NICE Proposed Review of Technology Appraisal Guidance Nos. 103 (part), 134, 146, 180: Etanercept for the treatment of adults with psoriasis; Infliximab for the treatment of psoriasis; Adalimumab for the treatment of psoriasis and Ustekinumab for the treatment of adults with moderate to severe psoriasis (Aug 2010)

BAD response to NICE Public Health Guidance consultation: Resources and environmental changes to prevent skin cancer (Aug 2010)

BAD response to NICE Single Technology Appraisal: Golimumab for the treatment of psoriatic arthritis (Jun 2010)

BAD response to NICE Guidelines Appraisal - pre-publication check: Improving outcomes for people with skin tumours including melanoma (update): The management of low-risk basal cell carcinomas in the community (Apr 2010)

BAD response to NICE: Guide to the technology appraisal appeals process (review) (Mar 2010)

BAD response to NICE Guidelines Appraisal: Metastatic malignant disease of unknown primary origin (Feb 2010)

BAD response to NICE Health Technology Appraisal: Etanercept, Infliximab and Adalimumab for the treatment of psoriatic arthritis (review) - assessment report (Jan 2010)

BAD response to NICE Guidelines Appraisal: Improving outcomes for people with skin tumours including melanoma (update): The management of low-risk basal cell carcinomas in the community (Dec 2009)

BAD response to NICE Health Technology Appraisal: Etanercept, Infliximab and Adalimumab for the treatment of psoriatic arthritis (review) - final scope (Aug 2009)

BAD response to NICE Appraisal Consultation Document (ACD) for the Single Technology Appraisal: Ustekinumab for the treatment of moderate to severe psoriaris (June 2009)

BAD response to NICE Appraisal Consultation Document (ACD) for the Single Technology Appraisal: Alitretinoin for the treatment of chronic eczema of the hand, refractory to steroids (May 2009)

BAD response to NICE: Topic Selection Process for Technology Appraisals (May 2009)

BAD response to NICE Proposed Single Technology Appraisal: Etanercept, infliximab, adalimumab (review) and golimumab for the treatment of psoriatic arthritis (April 2009) 

BAD response to NICE: NHS Evidence Accreditation Scheme (April 2009) 

BAD response to NICE: Updates to the Technology Appraisal Processes (February 2009) 

BAD response to NICE Single Technology Appraisal: Ustekinumab for the treatment of moderate to severe psoriaris (Jan 2009)

BAD response to NICE revised public health 'Process' and 'Methods' manuals (December 2008)

BAD response to NICE Proposed Single Technology Appraisal: Ipilimumab for the treatment of malignant melanoma (Oct 2008)  

BAD response to NICE Proposed Single Technology Appraisal: Vorinostat for the second line treatment for cutaneous T-cell lymphoma (Sep 2008)

BAD response to NICE Proposed Single Technology Appraisal: Alitretinoin for the treatment of severe chronic hand eczema  (Jun 2008)

BAD response to NICE Proposed Single Technology Appraisal: Ustekinumab for the treatment of moderate to severe psoriasis (May 2008)

BAD response to NICE: Review of Technology Appraisal guidance no. 81: the frequency of application of topical corticosteroids for eczema and Review of NICE Technology Appraisal guidance no. 82; on the use of pimecrolimus and tacrolimus for atopic dermatitis (eczema) (Oct 2007)

BAD response to NICE Proposed Health Technology Appraisal: Topical negative pressure for wound management (Oct 2007)  

BAD response to the NICE Single Technology Appraisal: Adalimumab for the treatment of psoriatic arthritis (September 2007) (Please note this evidence is similar to that given to NICE in Nov 2006)

BAD response to the NICE appraisal consultation document: Infliximab for the treatment of adults with psoriasis 

BAD response to the NICE Interventional Procedure consultation: Grenz rays therapy for inflammatory skin conditions (Oct 2007) (Sep 2007) (Jul 2007)

BAD response to the NICE draft guideline consultation: Atopic Eczema in Children (Jul 2007)

BAD second response to NICE draft guideline consultation: Atopic Eczema in Chidren (Jul 2007)

BAD response to the NICE Interventional Procedure consultation: Programme Methods Guide (Feb 2007)  

BAD response to the NICE Single Technology Appraisal: Adalimumab for the treatment of psoriatic arthritis (Nov 2006)

BAD response to the NICE Single Technology Appraisal: Inflximab for the treatment of psoriasis (Nov 2006)  

BAD response to the NICE consultation: Surgical Site Infection (May 2006)

BAD response to NICE consultation on Adalimumab for the treatment of moderate to severe psoriatic arthritis (Jan 2006)

BAD response to NICE consultation on Leflunomide for the treatment of moderate to severe psortiatic arthritis (Jan 2006)

NICE Review of Laser Therapy (Dec 2005)

Comments on the second draft of NICE Improving Outcomes for People with Skin Tumours including Melanoma
APPGS enquiry into the adequacy and equity of dermatology service provision (Sep 2005)

NICE Efalizumab and Etanercept for the treatment of plaque psoriasis response (Jul 2005)

NICE Social Value Judgements (Jun 2005)

NICE Improving Outcomes for People with Skin Tumours including Melanoma (Apr 2005)

BAD response to NICE Proposed Single Technology Appraisal: ABT-874 for the treatmentof moderate to severe chronic plaque psoriasis (Dec 2008)

BAD response to NICE Proposed Single Technology Appraisal: Etanercept for the treatment of moderate to severe plaque psoriasis in children and adolescents (Dec 2008)

BAD response to NICE Single Technology Appraisal: Alitretinoin for the treatment of chronic eczema of the hand, refractory to steroids (Dec 2008)

BAD response to Review of NICE Technology Appraisal Guidance Nos 103/ 134/ 146; on the use of etanercept and efalizumab for the treatment of adults with psoriasis, infliximab for the treatment of psoriasis and adalimumab for the treatment of psoriasis (Dec 2008)